Chicago, IL, United States of America

Jeffrey A Hubbell

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 4.8

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Jeffrey A Hubbell: Innovator in Immunotherapy

Introduction

Jeffrey A Hubbell is a prominent inventor based in Chicago, IL (US). He has made significant contributions to the field of immunotherapy, holding 3 patents that focus on innovative methods and compositions for treating immune responses and cancer.

Latest Patents

Hubbell's latest patents include "Compositions and methods concerning immune tolerance," which provides compositions comprising mannose-fused antigens to target mannose receptors. These compositions are designed to prevent immunity or reduce an immune response to protein-based drugs that would otherwise elicit such responses. Another notable patent is "Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines." This patent addresses the need for targeted therapies by providing compositions that limit systemic exposure and reduce side effects, specifically targeting cytokines to the tumor environment.

Career Highlights

Throughout his career, Jeffrey A Hubbell has worked with esteemed institutions such as the University of Chicago and Anokion SA. His work has significantly advanced the understanding and treatment of immune-related conditions and cancer therapies.

Collaborations

Hubbell has collaborated with notable individuals in his field, including Jun Ishihara and Ako Ishihara. These collaborations have contributed to the development of innovative solutions in immunotherapy.

Conclusion

Jeffrey A Hubbell's contributions to immunotherapy through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to influence advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…